Management of chemotherapy-induced neutropenia in patients with cancer: 2019 guidelines of the Italian Medical Oncology Association (AIOM)

Antonino C. Tralongo, Andrea Antonuzzo, Paolo Pronzato, Andrea Sbrana, Marianna Turrini, Federica Zoratto, Marco Danova

Research output: Contribution to journalReview articlepeer-review

Abstract

Neutropenia is the most frequent side effect of commercially available myelosuppressive drugs and its most significant complication is febrile neutropenia. It is associated with increased hospital admissions and higher probability of death. Prophylaxis with the administration of granulocyte colony-stimulating factor can prevent neutropenia caused by anticancer drugs. The correct administration of these drugs and the management of febrile neutropenia are extremely important in the treatment of patients with cancer.

Original languageEnglish
Pages (from-to)273-280
Number of pages8
JournalTumori
Volume106
Issue number4
DOIs
Publication statusPublished - Aug 1 2020

Keywords

  • AIOM
  • Febrile neutropenia
  • G-CSF
  • guidelines
  • myelotoxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Management of chemotherapy-induced neutropenia in patients with cancer: 2019 guidelines of the Italian Medical Oncology Association (AIOM)'. Together they form a unique fingerprint.

Cite this